Press Releases Moderna, Inc.

Stocks

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 10/07/2026 BST			After hours 01:00:00
68.27 ^USD	-10.83%		59.86	-12.31%

07-10	US Equity Indexes Rise as Diplomatic Engagements Between Washington, Iran Send Crude Oil Lower	MT
07-10	US Equities Rise, Oil Prices Ease as Trump Confirms Iran Talks	MT

Press Releases

07-09	Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026	AQ
07-08	Moderna Appoints Michael McDonnell to Board of Directors	AQ
06-25	Moderna Science Day Highlights Expanding Potential of mRNA Platform	AQ
06-18	Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine	AQ
06-17	Moderna to Host Investor Event - Science Day	AQ
06-16	Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028	AQ
06-09	Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome	AQ
06-02	Moderna to Present at Upcoming Conference in June 2026	AQ
06-01	Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus	AQ
05-12	Moderna Recognized by TIME as One of the World's Most Impactful Companies	AQ
05-06	Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010	AQ
05-04	Moderna : Presentation (Moderna 1Q26 Earnings Presentation FINAL)	PU
05-01	Moderna : Transcript (MRNA USQ Transcript 2026 05 01 1)	PU
05-01	Moderna : Earnings Presentation (Moderna 1Q26 Earnings Presentation FINAL)	PU
05-01	Moderna: Q1 Earnings Snapshot	AQ
05-01	Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates	AQ
04-22	Moderna : ESCMID 2026 (mRNA-1273 & mRNA-1283 Effectiveness and safety of variant updated Covid vaccines)	PU
04-22	Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate	AQ
04-21	Moderna : ESCMID 2026 (mRNA-1010 Phase 3 sequential administration in adults 50+)	PU
04-21	Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting	AQ
04-21	Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19	AQ
04-21	Moderna to Present at Upcoming Conferences in May 2026	AQ
04-19	Moderna : ESCMID 2026 (mRNA-1345 Phase 3 RSV revaccination 60+ study)	PU
04-19	Moderna : ESCMID 2026 (mRNA-1083 Phase 3 study in adults 50+ in Japan)	PU
04-17	Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting	AQ